A 6-year-old child with a history of dietary non-compliance presents with progressive tremor, rigidity, and behavioral changes. Plasma phenylalanine is markedly elevated (>30 mg/dL). To assess the severity of neurological damage and guide long-term management, which investigation is most appropriate?

## Neuroimaging in Untreated PKU ### Clinical Scenario This child has untreated or poorly controlled PKU with neurological manifestations (tremor, rigidity, behavioral changes). The question asks for the investigation to assess neurological damage and guide management. ### Investigation of Choice: Brain MRI **Key Point:** MRI of the brain is the most appropriate investigation to assess the structural and functional neurological damage caused by chronic hyperphenylalaninemia in PKU. **High-Yield:** Elevated plasma phenylalanine causes: 1. Competitive inhibition of neutral amino acid transporters (LAT1/LAT2) → reduced brain uptake of tyrosine, tryptophan, BCAA 2. Impaired myelin formation and white matter integrity 3. Neurotransmitter depletion (dopamine, serotonin, norepinephrine) 4. Excitotoxic damage from phenylalanine and its metabolites ### MRI Findings in Untreated PKU | Finding | Significance | |---------|-------------| | White matter hypomyelination | Indicates demyelination and impaired myelination | | Basal ganglia abnormalities | Correlates with movement disorders (tremor, rigidity) | | Cerebral atrophy | Reflects neuronal loss and irreversible damage | | T2 hyperintensity in periventricular regions | Suggests gliosis and chronic neuronal injury | **Clinical Pearl:** MRI findings in PKU correlate with: - Severity and duration of hyperphenylalaninemia - Degree of neurological deficit - Prognosis and potential for recovery with dietary intervention - Need for adjunctive therapies (e.g., neurotransmitter precursors, sapropterin) ### Why MRI Over Other Investigations? ```mermaid flowchart TD A[Child with PKU + neurological symptoms]:::outcome --> B{What to assess?}:::decision B -->|Enzyme defect?| C[Phenylalanine hydroxylase genotyping]:::action B -->|Metabolic control?| D[Plasma phenylalanine level]:::action B -->|Neurological damage?| E[Brain MRI]:::action E --> F[Assess white matter, basal ganglia, atrophy]:::outcome F --> G[Guide prognosis & treatment intensity]:::outcome ``` **Mnemonic:** **MRI-PKU-DAMAGE** = MRI Reveals Irreversible damage in PKU by showing white matter, basal ganglia abnormalities, and Myelination defects. ### Distinction from Other Tests - **Serum tyrosine/tryptophan:** Reflect secondary metabolic consequences, not neurological damage - **Phenylalanine hydroxylase genotyping:** Identifies the genetic mutation but does not assess neurological status or guide acute management - **Plasma homocysteine:** Elevated in some PKU variants (e.g., defects in folate metabolism) but not the primary concern in classical PKU [cite:Harrison 21e Ch 417]